Published in Mar Drugs on January 24, 2011
Brominated compounds from marine sponges of the genus Aplysina and a compilation of their 13C NMR spectral data. Mar Drugs (2011) 0.86
Anticancer and cancer preventive properties of marine polysaccharides: some results and prospects. Mar Drugs (2013) 0.82
Sample Processing Impacts the Viability and Cultivability of the Sponge Microbiome. Front Microbiol (2016) 0.76
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Sponge-associated microorganisms: evolution, ecology, and biotechnological potential. Microbiol Mol Biol Rev (2007) 5.24
Marine natural products. Nat Prod Rep (2001) 2.11
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol (1997) 1.89
Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology (1990) 1.53
Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf (2000) 1.38
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev (2000) 1.38
Sulfated seaweed polysaccharides as antiviral agents. Curr Med Chem (2004) 1.37
Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation. Glycobiology (2008) 1.27
Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues. J Biol Chem (1991) 1.14
Natural products with anti-HIV activity from marine organisms. Curr Top Med Chem (2003) 1.12
Marine natural products as lead anti-HIV agents. Mini Rev Med Chem (2003) 1.11
Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry (1994) 1.03
A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses (1996) 1.01
Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology (1998) 0.99
Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins from the brown alga Ecklonia cava. Biol Pharm Bull (2004) 0.98
Carbohydrate-carbohydrate interaction as a major force initiating cell-cell recognition. Glycoconj J (2004) 0.96
Antiretroviral activity of fucoidans extracted from the brown seaweed Adenocystis utricularis. Phytother Res (2009) 0.94
Naturally derived anti-HIV agents. Phytother Res (2005) 0.93
In vitro anti-HIV activity of sulfated cell-wall polysaccharides from gametic, carposporic and tetrasporic stages of the Mediterranean red alga Asparagopsis armata. Planta Med (2001) 0.91
A role for sulfated polysaccharide recognition in sponge cell aggregation. Exp Cell Res (1987) 0.88
Structural features and anti-HIV-1 activity of novel polysaccharides from red algae Grateloupia longifolia and Grateloupia filicina. Int J Biol Macromol (2007) 0.87
Isolation of a sulphated polysaccharide from a recently discovered sponge species (Celtodoryx girardae) and determination of its anti-herpetic activity. Int J Biol Macromol (2009) 0.86
Anti-HIV active petrosins from the marine sponge Petrosia similis. Biol Pharm Bull (2003) 0.83
A wide diversity of sulfated polysaccharides are synthesized by different species of marine sponges. Carbohydr Res (2000) 0.83
Isolation, fractionation, and preliminary characterization of a novel class of sulfated glycans from the tunic of Styela plicata (Chordata Tunicata). J Biol Chem (1986) 0.82
Recent studies on natural products as anti-HIV agents. Curr Med Chem (2000) 0.81
Isolation and NMR characterization of rosacelose, a novel sulfated polysaccharide from the sponge Mixylla rosacea. Carbohydr Res (2001) 0.79
Stages of HIV replication and targets for therapeutic intervention. Curr Top Med Chem (2003) 0.79
The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate. Acta Biochim Pol (1998) 0.79
Isolation and characterization of adociavirin, a novel HIV-inhibitory protein from the sponge Adocia sp. FEBS Lett (1998) 0.78
Isolation and characterization of cell adhesion molecules from the marine sponge, Ophlitaspongia tenuis. Biochim Biophys Acta (1991) 0.78
Isolation and characterization of niphatevirin, a human-immunodeficiency-virus-inhibitory glycoprotein from the marine sponge Niphates erecta. Eur J Biochem (1997) 0.77
Sponge cell aggregation. Mol Cell Biochem (1980) 0.77
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev (2004) 3.28
HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem (2004) 1.56
Identification of SOX3 as an XX male sex reversal gene in mice and humans. J Clin Invest (2010) 1.50
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol (2004) 0.98
Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies. Hum Gene Ther (2005) 0.93
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells. PLoS One (2010) 0.91
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol (2005) 0.89
Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs (2008) 0.89
HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol Immunol (2006) 0.88
Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood (2005) 0.84
HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay. J Neuroimmune Pharmacol (2011) 0.78
Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited. Virology (2009) 0.77
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS (2016) 0.77
Isomeric furanosesquiterpenes from the Portuguese marine sponge Fasciospongia sp. J Nat Prod (2008) 0.76
Biocatalytic formation of synthetic melanin: the role of vanadium haloperoxidases, L-DOPA and iodide. J Inorg Biochem (2011) 0.76
Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. Biotechnol Appl Biochem (2012) 0.75
Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target? Adv Virol (2010) 0.75
Assessing combinatorial strategies to multimerize libraries of single-domain antibodies. Biotechnol Appl Biochem (2012) 0.75